AIXIAL
AIXIAL is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at AIXIAL.
AIXIAL is a company.
Key people at AIXIAL.
Aixial Group is a leading Contract Research Organization (CRO) and part of the ALTEN Group, specializing in full-service clinical development from Phase I to IV trials, including post-marketing studies, data management, biostatistics, medical writing, regulatory affairs, and pharmacovigilance[2][3]. It primarily serves pharmaceutical, biotechnology, and medical device companies, focusing on complex therapeutic areas like oncology, cell & gene therapies, and rare diseases to accelerate innovative treatments to patients[2][3]. With over 1,100 experts across Europe, North America, and Asia, Aixial emphasizes efficiency, reliability, and flexibility through innovative CRO solutions, technology integration, and a patient-centric approach, generating approximately $37 million in revenue and employing around 285 people[2][4].
Aixial emerged as a specialized CRO within the ALTEN Group, building on over 25 years of experience in clinical trial technology and operations across more than 1,000 trials[3]. Its growth has been marked by expansion into global hubs, with headquarters in Paris, France (58 Ave De Wagram), and offices in key regions like Germany, Belgium, UK, Spain, USA, and India[2][4]. Pivotal moments include the development of its Technology & Innovation Office for integrating vendor tools and the Aixial R&D Lab's Smart Healthcare Research Program, which leverages AI for patient-centricity, real-world data, and value-based care—driving early traction in biotech and pharma partnerships[3].
Aixial rides the wave of AI-driven drug development and precision medicine, capitalizing on surging demand for therapies in oncology, gene editing, and rare diseases amid a biotech boom fueled by regulatory incentives and real-world evidence needs[2][3]. Its timing aligns with post-pandemic trial accelerations and global CRO market growth, where market forces like rising R&D costs ($2.6B+ per drug) and talent shortages favor specialized players like Aixial over generalists[3]. By influencing the ecosystem through AI innovations and vendor integrations, it enables faster, more accessible treatments, supporting pharma/biotech scalability in a landscape projected to exceed $100B in CRO spending by 2030[2][3].
Aixial is poised for expansion through AI-enhanced trials and deeper North America/Asia penetration, potentially scaling via strategic acquisitions or ALTEN synergies amid biotech funding rebounds[2][3]. Trends like real-world data integration and value-based care will shape its trajectory, evolving its influence from reliable executor to innovation leader in personalized medicine. As a CRO powerhouse, Aixial exemplifies how tech-savvy specialization accelerates life-saving therapies, tying back to its core mission of efficient, patient-focused clinical breakthroughs.
Key people at AIXIAL.
